Moss-based production of asialo-erythropoietin devoid of Lewis A and other plant-typical carbohydrate determinants

24.05.2012

Parsons J, Altmann F, Arrenberg CK, Koprivova A, Beike AK, Stemmer C, Gorr G, Reski R, Decker EL

Plant Biotechnol J. 2012;10(7):851-61

Protein therapeutics represent an increasing area in the pharmaceutical industry. Plants gain acceptance as attractive alternatives for high-quality protein production. In the moss Physcomitrella patens glycoengineering is feasible to eliminate planttypical N-glycosylation. Now, via precise gene targeting of galactosyltransferase and fucosyltransferase genes, we completely abolished the formation of undesired Lewis A-type glycan epitopes on moss-produced recombinant human erythropoietin.

BIOSS

Moss-based production of asialo-erythropoietin devoid of Lewis A and other plant-typical carbohydrate determinants